FDA Drug Safety Communication

by Pill Pals Customer Service | Jul 2, 2025 | News

AUDIENCE: Patient, Health Care Professional, Pharmacy, PediatricsISSUE: The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and...

FluLaval

by Pill Pals Customer Service | Jul 2, 2025 | News

STN: 125163Proper Name: Influenza VaccineTradename: FLULAVALManufacturer: ID Biomedical Corporation of QuebecIndications: For active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. FLULAVAL is...

Microsporidial Keratoconjunctivitis Caused by Vittaforma corneae, Sea of Galilee, Israel, 2022–2024

by Pill Pals Customer Service | Jul 2, 2025 | News

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released. Author affiliation: Meir Medical Center, Kfar Sava, Israel (A. Friehmann, F. El Zhalka);...

Drug Trials Snapshots: DATROWAY

by Pill Pals Customer Service | Jul 2, 2025 | News

HOW TO USE THIS SNAPSHOT The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar...

FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or

by Pill Pals Customer Service | Jul 2, 2025 | News

On July 2, 2025, the Food and Drug Administration granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory...